Insulin News and Research RSS Feed - Insulin News and Research

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.
Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals Ltd. ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical Ltd. [More]
MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome TherapeuticsTM LLC, today reported positive topline results from a proof of concept study testing whether its investigational drug, NM 505, can improve the tolerability of metformin, the first-line therapy for Type 2 diabetes worldwide. [More]
Working long hours in jobs of low socioeconomic status can increase the risk of diabetes

Working long hours in jobs of low socioeconomic status can increase the risk of diabetes

It is widely accepted that working long hours can be detrimental to one's health; not least because it leaves less time free to exercise and can cause stress and sleep disturbances. [More]
Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. [More]
Research report on biopharmaceutical and vaccine manufacturing markets

Research report on biopharmaceutical and vaccine manufacturing markets

The total biopharmaceutical manufacturing market is growing, according to Kalorama Information's report, Biopharmaceutical and Vaccine Production Markets. [More]
Dynamical glucometry may uncover new ways of understanding diabetes

Dynamical glucometry may uncover new ways of understanding diabetes

For millions of people in the United States living with Type 1 or Type 2 diabetes, measuring the daily rise and fall of blood glucose (sugar) is a way of life. [More]
Fast decline in insulin sensitivity seen in pre-diabetic South Asians

Fast decline in insulin sensitivity seen in pre-diabetic South Asians

People of south Asian descent who have Type 2 diabetes show a more rapid decline in fasting glucose levels than White individuals even before they develop the disease, new findings from the Whitehall II study suggest. [More]
Researchers discover new molecular mechanism that plays crucial role in age-dependent diabetes

Researchers discover new molecular mechanism that plays crucial role in age-dependent diabetes

Ageing of insulin-secreting cells is coupled to a progressive decline in signal transduction and insulin release, according to a recent study by researchers at Karolinska Institutet in Sweden. [More]
Gut hormone-drug combination therapy more effective at improving type 2 diabetes

Gut hormone-drug combination therapy more effective at improving type 2 diabetes

Combined treatment with a drug that mimics the action of a gut hormone and basal insulin is more effective at improving blood sugar control than other anti-diabetic treatments, with similar rates of hypoglycaemia (dangerously low blood sugar levels) and greater weight loss, a systematic review and meta-analysis published in The Lancet shows. [More]
ChromaDex signs NIAGEN supply agreement with Healthy Directions

ChromaDex signs NIAGEN supply agreement with Healthy Directions

ChromaDex Corp., an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has entered into an ingredient supply agreement with Healthy Directions, a direct-to-consumer nutritional supplement retailer and wholly-owned subsidiary of Helen of Troy Limited. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
Clinical trial of stem cell-derived therapy for patients with Type 1 diabetes

Clinical trial of stem cell-derived therapy for patients with Type 1 diabetes

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes. [More]
Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

Lilly and Boehringer Ingelheim's insulin glargine product gets marketing approval from EC

The European Commission granted marketing authorisation for Eli Lilly and Company and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. [More]
Beta-O2 receives grant from JDRF to study ßAir bio-artificial pancreas for treatment of T1D

Beta-O2 receives grant from JDRF to study ßAir bio-artificial pancreas for treatment of T1D

Beta-O2 announced today that it has received a $500K grant from JDRF. The grant will be used to help fund a $1M pilot human study of Beta-O2's ßAir bio-artificial pancreas, in development as a treatment and potential cure for type 1 diabetes (T1D). [More]
Regular consumption of mango by obese adults may lower blood sugar levels

Regular consumption of mango by obese adults may lower blood sugar levels

Research published in the journal Nutrition and Metabolic Insights found that regular consumption of mango by obese adults may lower blood sugar levels and does not negatively impact body weight. [More]
Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International plc announced today that it has introduced the first and only generic 2% topical testosterone gel, an authorized generic of FORTESTA® Gel (testosterone gel) CIII. [More]
Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Fractyl Laboratories Inc. today announced positive clinical data for the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes. [More]
ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. [More]
Coffee increases risk of prediabetes in young adults with hypertension

Coffee increases risk of prediabetes in young adults with hypertension

Coffee increases the risk of prediabetes in young adults with hypertension who are slow caffeine metabolisers, according to results from the HARVEST study presented at ESC Congress today by Dr Lucio Mos from Italy. People who drank more than three cups of coffee per day doubled their risk of prediabetes. [More]
Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

Scientists develop synthetic amino acid that can impact 3D structure of bioactive peptides

One of the greatest challenges in modern medicine is developing drugs that are highly effective against a target, but with minimal toxicity and side-effects to the patient. Such properties are directly related to the 3D structure of the drug molecule. [More]